Sagitta biotech

BENJAMIN DAMIEN, CEO
Liège, Belgium

INNOVATIVE VIRAL/RNA PLATFORM FOR INFECTIOUS DISEASES AND ONCOLOGY

Non-Confidential
General Presentation
Version May 21st 2025

Executive Summary

Our mission:

To offer a fast and effective way to develop vaccines for unmet needs



Sagitta Biotech is a vaccine company using an innovative Viral Vector/mRNA hybrid platform

- Two plasmids system transfected into human cells, able to express multiple antigens
- Our vaccines express antigens on their surface and deliver self-replicating RNA

Financials:

- To date: **€ 2 M** raised (private and public)
- Current Ask: **15M€ Series A** to complete first phase 1 Clinical Trial

Current Indications:

- Influenza (seasonal and pandemic)
- Flavivirus (multivalent vaccine)
- Others through collaborations (incl. Oncology)

Our innovative and versatile platform tackles single-handedly several unmet needs:

- Delivers new safe and efficient vaccines **in a few weeks**
- Can be adapted to **any viral disease**, in **single or multivalent vaccines**
- **Constant manufacturing process** for fast progress from R&D to manufacturing
- **High productivity** for high-throughput production in small footprint

Unmet Needs in Vaccines

1 Billion $

10 Years

Average time and budget to develop a new vaccine

This is ill-suited to the urgent demands of **pandemics and emerging diseases.**

There is a pressing need for **innovative vaccine platforms** that can produce **more effective and safer vaccines**, while also being **adaptable**, **rapid**, **cost-effective**, and **logistically straightforward**.

None of the existing Vaccine technologies are **fitting the bill**

Current Vaccine Development Strategies

sagittabiotech.com

CHARACTERISTICS	Attenuated Vaccines	mRNA Vaccines	Subunit vaccines	Recombinant vaccines
	 All MMR vaccines GSK's Rotavirus vaccine Sanofi's Oral polio vaccine	 Moderna's COVID Vaccine BioNTech's COVID Vaccine	 GSK's Zoster vaccine Merck's HPV vaccine	 Oxford/AZ's COVID vaccine NML's Ebola vaccine
Complete immune response				
Long lasting protection				
High Safety				
Fast development				
Cost-effectiveness				
Simple logistics / Local manufacturing				

*None of the currently existing technologies are able to achieve **all** the key vaccines characteristics*

Our Solution: New « Active Virosome » platform

Innovative platform

The platform is based on the **transfection of two plasmids** in production cells,
Which produces **non-replicative viruses able to deliver self-replicating RNA**

Immunogenic genes of the targeted virus

Measles virus functional genes (not surface antigen genes) Identical for ANY vaccine



Good humoral and cellular response confering protection at low dose

High-Performance Process

One-Week **constant manufacturing process, identical for any vaccines**

Transfection | **Viral Culture** | **Purification**

Transfection in HEK293 cells — Suspension in single use bioreactor — Precipitation and TFF filtration

1 day — 72 hours — 2 Days + QC/ release

Constant manufacturing
Low COGS / Low CAPEX
Easy distributed manuf

Platform Benefits

Our platform answers the requirements to tackle single-handedly most unmet needs in infectious diseases :

Strong B and T immunogenicity, with long-lasting immunity

- **High and broad immunogenicity,** very close to natural infection
- Able to carry up to **6 different antigens** (Multivalent)
- Measles antigens removed **avoid pre-existing Measles immunity**

Cost-efficiency, Fast development and High productivity

- **Fast development, Easy to manufacture, easy to transfer**
- The manufacturing process is **identical for all vaccine candidates**
- **Able to tackle any viral disease** (including cancer treatments)
- **High productivity: 1 million doses per liter and** PER WEEK



Platform developed to be compliant with "Vaccine Platform technologies" guidelines (EMA's CVMP/IWP/286631/2021, and FDA's VSM 800,213 Vaccine back-bone platform) => CEPI's "100days mission"

The Vaccine Market is expanding in multiple segments

sagittabiotech.com

GLOBAL VACCINE MARKET

The global vaccine market will reach **100 Billion$ in 2026**, with a **CAGR of 17,5%** (Grandview research 2024).
A **large share of the growth resides in LMIC markets**

Within this market, **many unmet needs remain** :

- Influenza (Seasonal/Universal) : >1B$
- Influenza (Pandemic) : Up to 15B$
- Respiratory Syncytial Virus: 2B$
- Epstein-Barr virus: 7B$
- YF, Zika and other flaviviruses : 2B$
- Ebola and other filoviruses : 0,5B$

Those markets can only be **tackled with specific technologies**

ONCOLOGY

Cancer vaccines market size was valued at **12.14 Billion$** in 2024 to **42.58 billion$ by 2032,** with a **CAGR of 17.0%**
(Fortune business insights 2024).

VETERINARY VACCINE MARKET

The vet vaccine market is estimated to reach **10Billion$ in 2027**, with a **CAGR of 10,6%** (Markets&Markets, 2024).



Source : Grandview research 2024

Preliminary Pre-Clinical data – Flu vaccine candidate

Our Flu vaccine candidate induces strong neutralizing antibodies (left), as well as CD4+ and CD8+ T cell response (right), similar to a wild-type flu virus. The response is very similar to natural infection (red).

Antibody induction after immunization



T cell restimulation using Flu Virus



Full preclinical package will be available **End 2025** : Efficacy and challenge (Mice and Ferrets), TOX and PK (Rats/Rabbits)
Full CMC and manufacturing packages, to complete our IMPD dossier, ready for IND in 2026

Intellectual property and portfolio

Nov 2024

Positive freedom to operate report

- Infectious diseases
- Oncology
- Measles vector

Feb 2025

Foundational patent filing in EP

- Composition of Matter (CoM) claims
- 2-plasmid platform and Measles-based virosomes
- Full ownership to Sagitta

Europäisches Patentamt
European Patent Office
Office européen des brevets

Acknowledgement of receipt

We hereby acknowledge receipt of your request for grant of a European patent as follows:

Submission number	14046970
Application number	EP25158639.2
File No. to be used for priority declarations	EP25158639
Date of receipt	18 February 2025
Your reference	PAT-21235-EP00
Applicant	Sagitta Biotech
Country	BE
Title	VIRUS-BASED EXPRESSION OF PR OTEINS AND GENES

2025+

Future IP Prosecution

- Additional CoM patent filings
- Platform improvements
- Additional uses

Pipeline With Staggered Development

sagittabiotech.com

Sagitta's constant manufacturing platform will allow quick follow-on developments once the first asset has reached Clinical stage.
We are expecting to develop a pipeline with one new product per year



* 0,9M€ Equity + 1.1M€ Non dilutive

Revenue model - road to global market



Multi-stakeholder partnerships

- Key government initiatives (CEPI, etc)
- Leading academic centers
- Leading local/global vaccine players

Development of vaccine candidates until Phase 1 trials

Revenues through:

- Out-licensing
- Co-development partnerships with local/global pharma

Licence deal Structure

- Upfront, Milestones and Royalties
- 100M$-500M$/asset based on recent benchmarks deals

Beyond vaccines : Other potential applications

Our virosomes can carry a wide array of proteins and genes to target specific cell types and indications

- **Oncology:** Targeted delivery of anti-tumor immune activators to tumor cells or dendritic cells
- **Gene therapy:** Targeted delivery of up to 18000 bp of genes
- **Autoimmunity:** Transforming TCells and NK cells with CARs *in vitro* or in vivo



Targeted virosomes

- Tumor cells expressing neoantigens
- Primary cell with genetic disease
- T cells or NK cells

Deep expertise in science, pharma and funding

sagittabiotech.com

EXECUTIVE TEAM

Benjamin DAMIEN (PhD, MBA) -

CEO

22 years in biotech management and drug development (BioXpr, Targetome, Univercells, Delta Diagnostics).

Raised over 35M€ from dilutive and non dilutive sources and participated to the creation of 15 biotech startups in Europe.

Hélène GAZON (PhD) -

Head of Research

Immunology – Oncology

10 years of experience in vaccine and oncology development (PDC*Line)

Experienced R&D and production team, with industrial bkgd

With additional support from external experts, CRO and CDMO companies

BOARD OF DIRECTORS

Didier ALLAER

President of the Board

Business AngelFounder of Diagenode, and board member of several startups in Biotech/medtech

Frederic SCHYNTS

Director (NOSHAQ)

25 years of experience in virology, immunology and vaccine development (GSK Vaccines) Independent consultant in drug and biological developments

Philippe MONTEYNE

Independent Director

20 years of experience in Biotech & Pharma (GSK, Sanofi)Developed Cervarix End-to-End, VC Fund Partner (Fund+, Aliath)

SCIENTIFIC ADVISORY BOARD

Arnaud DIDIERLAURENT (CH)

Immunology expert

Prof. of Transl. Immunology, U Geneva & Director of Geneva Vaccine center Vaccine Dvpt at GSK 13years

Veronique FLAMANT (B)

Immunology expert

20 years of experience in Biotech & Pharma (GSK, Sanofi)Developed Cervarix End-to-EndVC Fund Partner (Fund+, Aliath)

Conor CAHILL (B)

Vaccine expert

Over 20 years in drug and vaccine development, from R&D to clinical/regulatory

Louis-Marie BLOYER (F)

Viral biology expert

15 Years of viral biology research, notably on Measles

Jennet BEESLEY (UK)

Molecular Biology expert

25 Years experience in gene expression and recombinant protein production.

Take home messages

Sagitta ambitions to become a best-in-class platform for the development of vaccines for Infectious Diseases and Oncology with its innovative self-replicating RNA/viral vector platform

- This technology will be key to tackle ***unmet medical needs***, and has the capacity to significantly speed up development of new cost-effective products, thanks to its « plug in» platform
  https://vitalhubhealth.com/
- The company is developing its ***own vaccine & oncology pipeline***, until Human PoC
- We are looking for ***collaborations with institutions/Companies*** to tackle unmet needs in the vaccine field



Sagitta is part of the VITAL Accelerator from BARDA (US) https://vitalhubhealth.com/

Sagitta biotech

BENJAMIN DAMIEN, CEO

+32 475 429313

b.damien@sagittabiotech.com

www.sagittabiotech.com

Liège, Belgium